

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)



(10) International Publication Number
WO 2023/211812 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 405/14 (2006.01)
C07D 311/16 (2006.01) C07D 417/12 (2006.01)
C07D 405/06 (2006.01) C07D 417/14 (2006.01)
C07D 405/12 (2006.01) A61K 31/352 (2006.01)

(21) International Application Number:

PCT/US2023/019588

(22) International Filing Date:

24 April 2023 (24.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/334,447 25 April 2022 (25.04.2022) US
63/417,823 20 October 2022 (20.10.2022) US

(71) Applicant: NESTED THERAPEUTICS, INC. [US/US];
1030 Massachusetts Avenue, Suite 401, Cambridge, MA
02138 (US).

(72) Inventors: BELANGER, David; 1030 Massachusetts Avenue,
Suite 401, Cambridge, MA 02138 (US). FITZGER-
ALD, Mark; 1030 Massachusetts Avenue, Suite 401, Cam-
bridge, MA 02138 (US). HALE, Jeffrey; 1030 Massa-
chusetts Avenue, Suite 401, Cambridge, MA 02138 (US).
HALE, Michael; 1030 Massachusetts Avenue, Suite 401,
Cambridge, MA 02138 (US). HAN, Yongxin; 1030 Mass-
achusetts Avenue, Suite 401, Cambridge, MA 02138 (US).
ORTWINE, Daniel, F.; 1030 Massachusetts Avenue, Suite
401, Cambridge, MA 02138 (US). OZEN, Aysegul; 1030
Massachusetts Avenue, Suite 401, Cambridge, MA 02138
(US).

(74) Agent: DAVIS, Steven, G. et al.; McCarter & English, LLP,
265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS



(57) Abstract: The present invention is related to compounds of
structure (I) as mitogen-activated protein kinase (MEK) and/or
ERK inhibitors. (Formula (I)). The variables are described herein.

WO 2023/211812 A1